- Athabasca Fission Minerals (TSX-V: AFMC) raised $18M CAD at $0.50/unit for uranium exploration in Saskatchewan’s Athabasca Basin, with a 12-month insider lockup.
- NeuralDx Health (CSE: NRDX) raised $16M CAD at $2.25/share, offering an AI diagnostic SaaS platform with two signed provincial contracts and a 6-month lockup.
- Both deals carried institutional backing — Haywood Securities and Canaccord for AFMC; Beacon Securities and MedNorth Capital’s $3.5M anchor position for NRDX.
- Uranium spot prices above USD $85/lb (CAD ~$121/lb) and a rising TSX Composite at 35,984 provide a constructive backdrop for both new issues this week.
Canada’s new-listings pipeline remained active heading into the back half of October 2026, with two companies making their market debuts on the TSX Venture Exchange and the Canadian Securities Exchange respectively. Together, Athabasca Fission Minerals Corp. (TSX-V: AFMC) and NeuralDx Health Inc. (CSE: NRDX) raised a combined $34 million CAD — a healthy haul in a week when the TSX Composite added 0.90% to close at 35,984. Both listings drew institutional backing and offer retail investors distinct risk-reward profiles worth examining closely.
Athabasca Fission Minerals Corp. (TSX-V: AFMC) — Uranium Exploration
Athabasca Fission Minerals listed on the TSX Venture Exchange on October 14, 2026, pricing its IPO at $0.50 per unit and raising $18 million CAD through a brokered private placement. Each unit consists of one common share and one-half of a warrant exercisable at $0.70 for 24 months — a common structure on the TSX-V that sweetens the deal for early backers. The company controls approximately 142,000 hectares of prospective uranium ground in Saskatchewan’s Athabasca Basin, one of the world’s highest-grade uranium districts. In plain terms: AFMC is a pure-play exploration-stage company that will use the IPO proceeds to fund drilling campaigns over the next 18 months, with no revenue and no producing assets yet.
The offering was led by Haywood Securities as bookrunner, with PI Financial and Canaccord Genuity participating as co-underwriters — a syndicate that signals meaningful institutional interest in the uranium exploration theme. Uranium spot prices have remained elevated above USD $85/lb (roughly CAD $121/lb at today’s 1.4241 exchange rate), keeping the Athabasca Basin firmly in the spotlight. Insider lockup is 12 months from the date of listing, meaning founding shareholders and management cannot sell their shares until at least October 14, 2027. Minimum board lot is 1,000 shares at $0.50, making the entry cost just $500 CAD — highly accessible for retail investors, though exploration-stage uranium carries significant binary risk tied to drill results.
NeuralDx Health Inc. (CSE: NRDX) — AI-Powered Diagnostics
NeuralDx Health made its CSE debut on October 10, 2026, listing at $2.25 per share and raising $16 million CAD via a prospectus offering — larger than typical for a CSE debut and a sign of genuine institutional demand. The Vancouver-based company has developed a proprietary machine-learning platform that analyzes medical imaging data (primarily CT and MRI scans) to flag early-stage neurological anomalies, including early indicators of Alzheimer’s disease and stroke risk. NeuralDx is not a drug company; it is a software-as-a-service business that licenses its diagnostic platform to hospital networks and radiology clinics. The company reports two signed provincial health authority contracts and is targeting U.S. FDA 510(k) clearance in Q2 2027.
The deal was sole-bookrun by Beacon Securities, with participation from Toronto-based health-tech fund MedNorth Capital Partners, which took a $3.5 million CAD anchor position. That anchor allocation — roughly 22% of the raise — is a meaningful quality signal for a CSE listing. Insider lockup is 6 months, expiring around April 10, 2027, which is shorter than AFMC’s and worth monitoring for potential selling pressure. At $2.25 per share with no warrants attached, NRDX is a cleaner, higher-priced instrument than a typical TSX-V unit offering. Investors should note that NeuralDx posted CAD $1.2 million in revenue for the fiscal year ended June 30, 2026, making it early-stage but not pre-revenue.
At a Glance: October 2026 New Listings Compared
| Company | Ticker | Exchange | Sector | IPO Price | Funds Raised | Lockup |
|---|---|---|---|---|---|---|
| Athabasca Fission Minerals | AFMC | TSX-V | Uranium Exploration | $0.50/unit | $18M CAD | 12 months |
| NeuralDx Health Inc. | NRDX | CSE | AI / MedTech | $2.25/share | $16M CAD | 6 months |
The broader market backdrop is supportive: the TSX Composite’s 0.90% gain on listing day — while the S&P 500 and NASDAQ were marginally negative — underscores a degree of domestic resilience that can favour new Canadian issues. Retail investors considering either name should review the full prospectus filed on SEDAR+, paying particular attention to use-of-proceeds schedules and management’s prior track records before committing capital.
